Drug Type Small molecule drug |
Synonyms Gracevit, Sitafloxacin, Sitafloxacin (USAN) + [6] |
Mechanism Bacterial DNA gyrase inhibitors, Topoisomerase IV inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date JP (25 Jan 2008), |
RegulationPriority Review (CN) |
Molecular FormulaC38H42Cl2F4N6O9 |
InChIKeyMPORYQCGWFQFLA-ONPDANIMSA-N |
CAS Registry163253-35-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02475 | Sitafloxacin Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | CN | 01 Feb 2019 | |
Bacterial Infections | JP | 02 Jun 2008 | |
Gingivitis | JP | 25 Jan 2008 | |
Respiratory Tract Infections | JP | 25 Jan 2008 | |
Urinary Tract Infections | JP | 25 Jan 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bronchitis, Chronic | Phase 3 | CN | 26 Jun 2017 | |
Community-Acquired Infections | Phase 3 | CN | 26 Jun 2017 | |
Tonsillitis | Phase 3 | CN | 26 Jun 2017 | |
Complicated urinary tract infection | Phase 3 | CN | 08 Dec 2012 | |
Complicated urinary tract infection | Phase 3 | CN | 08 Dec 2012 | |
Pneumonia | Phase 3 | CN | 02 Dec 2012 | |
Pneumonia | Phase 3 | CN | 02 Dec 2012 | |
Acute respiratory infections | Phase 2 | CN | 26 May 2015 | |
Acute urinary tract infection | Phase 2 | CN | 26 May 2015 | |
Laryngitis | Phase 2 | CN | 12 Mar 2015 |
Not Applicable | 114 | wtnsjzdfuy(oekhhhnqej) = uyiklyuigc cmtctctbqf (hvijebeozv ) | - | 01 Jan 2022 |